secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0001104659-22-055918
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist reports Q1 net loss $20.9M; initiates rusfertide Phase 3 VERIFY in PV
--------------------------------------------------------------------------------

- Q1 2022 net loss $20.9M ($0.43 per share) vs $24.0M ($0.54) in Q1 2021.
- License and collaboration revenue $25.7M, including $25M milestone from Janssen for PN-235.
- Cash and securities $305.3M; runway through end of 2024.
- Initiated Phase 3 VERIFY study of rusfertide in polycythemia vera; enrollment completion expected 1H 2023.
- Phase 2 IDEAL study of PN-943 in UC met proof-of-concept at 150 mg BID; engaged PJT Partners for partnering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465922055918/0001104659-22-055918-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465922055918/tm2214413d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-055918

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer